Bioquell UK Ltd (www.bioquell.com) is celebrating the sale of its 200th Bioquell Qube. This milestone high performance isolator has been supplied to a major international pharmaceutical company.
Ian Johnson, Bioquell’s Executive Chairman, commented: “Bioquell can be proud of setting another milestone with the production of the 200th Bioquell Qube aseptic workstation. In fact, I am delighted to report that we have seen a 90% increase in sales of the popular isolator system compared to the same period last year.“
Bioquell’s Qube aseptic workstation incorporates the company’s innovative Hydrogen Peroxide Vapour technology for rapid bio-decontamination, reduced risk and major cost benefits. It achieves more in less time by starting the decontamination cycle without needing to first reach temperature or humidity levels to begin the process. The Hydrogen Peroxide Vapour provides a 6-log sporicidal kill over every exposed surface.
Equipped with an optional, integrated Merck Millipore Sigma Symbio Flex Sterility Test Pump, the Bioquell Qube allows operators to perform sterility testing by direct inoculation or membrane filtration in an aseptic Grade A environment providing assurance of process integrity. It also provides a controlled means of loading and removing the product from the workstation’s enclosure.
Bioquell Qube isolator technology is also ideal for the critical nature of CAR-T, gene and cell therapy, helping to reduce the potential risk of contamination by microorganisms or another patient’s cells through product handling and environmental exposure. With operators able to sit at the Bioquell Qube work station, the transformative process can be conducted within a guaranteed safe and productive ISO 5/EU Grade A environment, providing an added level of protection from potentially costly and hazardous bio-contamination.
The Bioquell Qube offers up to three chambers (two gloves in each) with optional material pass-throughs and Rapid Transfer Ports (RTP) designed to meet workflow needs. It enables decontamination of materials in one chamber whilst operatives work in another, and offers aseptic-hold retention for typically seven days depending on protocols. For most organisations starting with one system, Bioquell offers the option to add chambers at a later date to suit capacity requirements.
Constructed from tough and hard-wearing polypropylene, Bioquell’s Qube can be installed and validated within 12 weeks from the order date.
It incorporates a wide range of advanced features including a password protected colour touchscreen control panel interface which allows easy navigation via intuitive icons. Cycles are validated and pre-programmed for quick and simple start up.